Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.66 |
| ▸ | FBP1 | P09467 | 2/20 | 0.66 |
| ▸ | AURKA | O14965 | 1/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.66 |
| ▸ | INSR | P06213 | 1/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.66 |
| ▸ | FLT4 | P35916 | 1/20 | 0.66 |
| ▸ | KDR | P35968 | 1/20 | 0.66 |
| ▸ | CLK1 | P49759 | 1/20 | 0.66 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.66 |
| ▸ | TEK | Q02763 | 1/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.66 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24979 | 0.91 | EGFR (0.68) | EGFRFBP1AURKAERBB2INSR | |
| SCHEMBL2971582 | 0.88 | FBP1 (0.64) | EGFRFBP1AURKAERBB2INSR | |
| SCHEMBL26876 | 0.87 | EGFR (0.83) | EGFRFBP1AURKAERBB2INSR | |
| SCHEMBL29362232 | 0.87 | EGFR (0.83) | EGFRFBP1AURKAERBB2INSR | |
| SCHEMBL15928080 | 0.86 | FBP1 (0.66) | EGFRFBP1AURKAERBB2INSR | |
| SCHEMBL15928219 | 0.86 | FBP1 (0.66) | EGFRFBP1AURKAERBB2INSR | |
| SCHEMBL26593 | 0.86 | FBP1 (0.71) | EGFRFBP1AURKAERBB2INSR | |
| Water SCHEMBL28549003 | 0.86 | EGFR (0.81) | EGFRFBP1AURKAERBB2INSR | |
| Hydrochloric Acid SCHEMBL28101874 | 0.86 | EGFR (0.81) | EGFRFBP1AURKAERBB2INSR | |
| SCHEMBL17538536 | 0.85 | EGFR (0.65) | EGFRFBP1AURKAERBB2INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020011020-A1 | MEFATINIB COMPOSITION, RELATED COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州华东医药集团生物医药有限公司 | 2020-01-16 | — | — | WO | disclosed |
| US-20150065709-A1 | Aminoquinazoline Derivative And Use Thereof In Preparing Anti-Malignant Tumor Medicament | METABOMICS, INC. (CN) | 2015-03-05 | — | — | US | disclosed |
| US-20150065709-A1 | Aminoquinazoline Derivative And Use Thereof In Preparing Anti-Malignant Tumor Medicament | METABOMICS, INC. (CN) | 2015-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065709-A1 | Aminoquinazoline Derivative And Use Thereof In Preparing Anti-Malignant Tumor Medicament | ERBB2, EGFR, ERBB4 | EGFR 2/4885FBP1 2385/4885AURKA 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.